US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
biotech · Acute Respiratory Distress Syndrome (ARDS) · Allergic Contact Dermatitis · EDSA
Edesa Biotech
Edesa Biotech drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Markham, CA HQ
2015 Founded
22 Employees
Public company Type
EDSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Markham, CA
- Founded
- 2015
- Employees
- 22
- Programs
- 5
- Drugs
- 5
- Patents
- 0
Edesa Biotech pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Edesa Biotech drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Edesa Biotech's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Edesa Biotech in public FDA and regional records.
-
vilobelimab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Edesa Biotech's portfolio. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor